POPULARITY
18 episodes with SCLC
23 episodes with SCLC
21 episodes with SCLC
23 episodes with SCLC
22 episodes with SCLC
19 episodes with SCLC
30 episodes with SCLC
18 episodes with SCLC
20 episodes with SCLC
23 episodes with SCLC
10 episodes with SCLC
10 episodes with SCLC
22 episodes with SCLC
6 episodes with SCLC
8 episodes with SCLC
6 episodes with SCLC
22 episodes with SCLC
6 episodes with SCLC
6 episodes with SCLC
9 episodes with SCLC
5 episodes with SCLC
4 episodes with SCLC
14 episodes with SCLC
2 episodes with SCLC
5 episodes with SCLC
4 episodes with SCLC
3 episodes with SCLC
Radiation therapy is a powerful and non-invasive tool in the management of small cell lung cancer (SCLC), but radiation oncologists are not always fully integrated into the care team. In this episode, CANCER BUZZ speaks with Charles B. Simone, II, MD, FASTRO, FACRO, FACR, chief medical officer of the New York Proton Center and radiation oncologist at Memorial Sloan Kettering Cancer Center, about strategies to improve collaboration between radiation and medical oncology. He discusses some of the biggest barriers and greatest rewards of enhancing this partnership and expanding access to radiation therapy for SCLC. Guest: Charles B. Simone, II, MD, FASTRO, FACRO, FACR Research Professor and Chief Medical Officer New York Proton Center Radiation Oncologist Memorial Sloan Kettering Cancer Center New York, NY "While we don't have large, randomized trials really telling us how the modalities should be sequenced, that really should be a discussion and personalized for each patient." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR "After a slow 20 years of limited progress, this last half a decade has seen dramatic progress for small cell, and with that, the multidisciplinary collaboration is even more important." —Charles B. Simone, II, MD, FASTRO, FACRO, FACR Resources: Comprehensive Quality Care for Patients With Small Cell Lung Cancer Small Cell SMASHERS: How Community, Advocacy, and Emerging Science Are Changing the Narrative in Small Cell Lung Cancer
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy for ES-SCLC (9:31) Considerations with immunotherapy for ES-SCLC (13:12) Curability of SCLC with systemic therapy (15:17) Data with chemoimmunotherapy for patients with poor performance status (25:55) Future developments in therapy for SCLC (30:11) Rapid fire: Small Cell 101 (35:45) CME information and select publications
Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics: Overview of small cell lung cancer (SCLC) (0:00) First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50) Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36) Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46) Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21) CME information and select publications
Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIPT
In today's episode, we spoke with Jacob Sands, MD. Dr Sands is the associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Sands discussed the rapidly evolving treatment landscape for small cell lung cancer (SCLC), emphasizing both the progress made with immunotherapy and the ongoing challenges associated with this aggressive disease. He noted that outcomes now vary widely, with some patients experiencing long-term durable disease control following checkpoint inhibitor therapy, while others continue to have limited benefit from currently available treatments.A major focus of the discussion centered on tarlatamab-dlle (Imdelltra), the DLL3-targeting bispecific T-cell engager approved for relapsed SCLC. Sands described tarlatamab as a “new paradigm” therapy, highlighting results from the phase 3 DeLLphi-304 trial (NCT05740566) showing superiority in progression-free survival, overall survival, symptom improvement, and toxicity outcomes vs chemotherapy in the second-line setting. He also reviewed the evolution of DLL3 as a therapeutic target, explaining how earlier efforts with rovalpituzumab tesirine (Rova-T) helped establish the foundation for newer, more effective DLL3-directed approaches. The conversation also explored the growing role of molecular subtyping in SCLC, including emerging data involving ASCL1, NEUROD1, and POU2F3 transcription factor subsets. Although Sands cautioned that these findings remain investigational, he noted that subtype-driven treatment selection may eventually help personalize therapy in SCLC.Sands also addressed real-world experience with tarlatamab, including higher observed rates of cytokine release syndrome and neurologic toxicities among patients who would not have qualified for clinical trials. Despite these risks, he emphasized that many heavily pretreated patients with poor performance status or brain metastases have still achieved meaningful and durable clinical benefit.Finally, the discussion covered recent updates to National Comprehensive Cancer Network guidelines, including the establishment of tarlatamab as a preferred second-line standard of care regardless of chemotherapy-free interval. Looking ahead, Sands highlighted the growing pipeline of investigational therapies in SCLC, including CAR T-cell therapies, antibody-drug conjugates, radioligand therapies, and additional T-cell engagers, stressing the importance of clinical trial referral and collaboration between academic and community oncology centers.
Send us Fan MailTogetherness is not a warm slogan, it's the only way we meet the scale of what's in front of us. From the start, we press on a simple question: how do you remember the past honestly without letting it turn into bitterness? In this episode, Bishop Wright has a conversation with Senator Jon Ossoff about faith, leadership, and what it takes to build a better world when the headlines feel like a steady stream of bad news. Ossoff traces his moral education through the legacy of Congressman John Lewis and the civil rights movement in Georgia, including the historic alliance between Black and Jewish communities in the South. He shares the powerful symbolism of being sworn into the US Senate on scripture belonging to Rabbi Jacob Rothschild, the Atlanta rabbi whose temple was bombed in 1958 for supporting Dr. King and the SCLC. They discuss what interfaith coalition building looks like when it's real, not performative, and why serious faith traditions should pull us alongside each other when the stakes are high. Listen in for the full conversation. Born and raised in Georgia, Senator Jon Ossoff serves as our Senior United States Senator. Since his election, Sen. Ossoff has built bipartisanship in the Senate to achieve meaningful legislative results for Georgia — even in a divided Congress. In his first two years in office, Sen. Ossoff passed into law more standalone bills than any other freshman Senator. Sen. Ossoff's legislative achievements include laws to protect children online; to strengthen public safety; to tackle the opioid epidemic and prevent fentanyl trafficking across the Southern Border; to investigate unsolved lynchings and Civil Rights murders; to strengthen mental health care services for veterans; and to fight corruption and improve security in U.S. prisons. Mentored by civil rights legend Congressman John Lewis, Sen. Ossoff previously led a small business that produced investigative journalism exposing war crimes, public corruption, human trafficking, and organized crime. Sen. Ossoff lives with his wife, Dr. Alisha Kramer, and two daughters in Atlanta.Support the show Follow us on IG and FB at Bishop Rob Wright.
Send us Fan MailFor more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change.Today, we're joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( https://www.amgen.com/ ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients.If you've been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions. That idea is now playing out in the clinic through approaches like bispecific T-cell engagers, which physically link immune cells to cancer cells and force a targeted immune response - offering a new way to go after tumors that have historically been very hard to treat.Dr. Coxon earned her D. Phil in Molecular Biology from the University of Oxford and completed postdoctoral training in vascular biology at Harvard Medical School and Brigham and Women's Hospital. She has built her career at the intersection of cutting-edge biology and strategic drug development, contributing to Amgen's pipeline in areas of significant unmet need, including lung cancer.#SmallCellLungCancer #SCLC #CancerBreakthrough #Immunotherapy #CancerResearch #Biotech #Amgen #DrugDevelopment #Oncology #CancerTreatment #BiTE #BispecificAntibodies #InducedProximity #PrecisionMedicine #ClinicalTrials #MedicalInnovation #FutureOfMedicine #LungCancerAwareness #TranslationalMedicine #Biology #SciencePodcast #HealthcareInnovation #CancerTherapy #Pharma #NextGenMedicineSupport the show
Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape. You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes. Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope. Guests: Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf Video: https://youtu.be/RCwJvdcOS-4 For more information, visit lcfamerica.org.
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC). Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included: • The role of surgery and adjuvant chemotherapy in early-stage SCLC. • Insights into the ADRIATIC study, which highlighted the efficacy of Durvalumab in limited-stage disease. • The debate surrounding prophylactic cranial irradiation (PCI) and its implications for patient care. • The latest findings from the IMforte study, showcasing the combination of Atezolizumab and Lurbinectedin as a new standard of care in extensive-stage SCLC. • The promising results of Tarlatamab in the second-line setting and its impact on overall survival. Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers
In today's episode, we spoke with Alissa Cooper, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Cooper discussed recent advances that have reshaped the treatment paradigm for small cell lung cancer (SCLC), particularly in the relapsed setting. She highlighted the FDA approval of tarlatamab-dlle (Imdelltra), a DLL3-targeting T-cell engager, as one of the most impactful developments in recent years. Despite this progress, Cooper emphasized that the frontline standard of care has remained largely unchanged, continuing to rely on platinum-based chemotherapy in combination with immunotherapy. She noted that, although ongoing clinical trials are exploring biomarker-driven strategies and novel combinations, a more personalized first-line approach has yet to be established.The conversation also explored real-world treatment sequencing and decision-making at the point of relapse. Cooper explained that, whenever feasible, oncologists aim to enroll patients in clinical trials or initiate treatment with tarlatamab. However, logistical barriers, including trial screening requirements and the need for monitored administration of T-cell engagers, can delay care. In cases of rapidly progressing disease, oncologists may instead turn to cytotoxic therapies such as lurbinectedin (Zepzelca) or use localized approaches like radiation to achieve faster disease control.The importance of multidisciplinary coordination was another key theme. Cooper underscored that SCLC management requires rapid collaboration among medical oncologists, radiation oncologists, pulmonologists, pathologists, and supportive care teams. Early involvement of palliative care is also critical, given the aggressive nature of the disease and high symptom burden.Additionally, she highlighted the essential role of oncology pharmacists, nursing teams, and structured patient education. Clear toxicity management protocols, dose-modification guidelines, and comprehensive patient education visits help ensure safe treatment delivery and empower patients to manage adverse effects.Looking ahead, Cooper described an “embarrassment of riches” in emerging therapies and targets under investigation. Beyond DLL3, novel approaches targeting markers such as SEZ6 and B7-H3, as well as next-generation antibody-drug conjugates and trispecific T-cell engagers, are showing early promise. However, key questions remain regarding biomarker selection, treatment sequencing, and real-world effectiveness, particularly for patients who would not meet clinical trial eligibility criteria.Finally, she emphasized that improving coordination between community and academic centers is essential to ensuring timely access to innovative therapies and clinical trials. Strengthening communication pathways and referral processes may help bridge gaps in care and improve outcomes for patients with this aggressive disease.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KVU865. CME/CPE/IPCE credit will be available until April 25, 2027.The 3 P's of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.
In today's episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized the importance of quickly confirming a patient's diagnosis and initiating treatment to avoid missing the critical window where chemotherapy could provide meaningful clinical benefit. However, Leal noted that the field still lacks predictive biomarkers to guide treatment selection. Accordingly, current strategies, including chemoimmunotherapy, maintenance approaches, and second-line options like tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca) are largely chosen based on clinical factors such as disease burden, comorbidities, and patient preferences.The conversation then shifted to the challenge of treating patients who may not meet traditional clinical trial eligibility criteria due to poor performance status, comorbidities, or social vulnerabilities. Leal stated that a multidisciplinary approach, including collaboration with supportive care teams, is essential to optimize outcomes for these patients. She noted that potential solutions to restrictive trial eligibility criteria may include decentralizing trials, improving collaboration between academic and community centers, and providing additional patient support such as transportation and care navigation services.Looking ahead, Leal emphasized the need for community practices to prepare for emerging therapies, including antibody-drug conjugates and novel immunotherapy approaches. Successfully integrating these treatments into everyday practice will require education, infrastructure development, and multidisciplinary collaboration, Leal imparted.
In today's episode, we spoke with Misty D. Shields, MD, PhD, about the realities of treating patients with small cell lung cancer (SCLC) in the community setting and how emerging therapies are shaping care delivery. Dr Shields is a translational medical oncologist at Indiana University Health in Indianapolis. In our exclusive interview, Dr Shields highlighted the urgency associated with SCLC treatment, an aggressive malignancy that often presents with rapid symptom onset and widespread metastases. The conversation also underscored the importance of multidisciplinary care. This approach is especially critical in light of expanded treatment options such as chemoimmunotherapy regimens, second-line therapies including tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca), along with clinical trials evaluating antibody-drug conjugates and radioligand therapies.From a practical standpoint, integrating these therapies into the community setting presents logistical challenges. Shields noted that although immunotherapy has been rapidly adopted since its introduction into standard care around 2019, newer agents require additional infrastructure. Education gaps remain another key issue. The growing availability of clinical trials and new treatment strategies makes it essential to guide patients through potential care pathways, helping them understand options across the first-line, maintenance, and relapsed settings.Looking ahead, molecular characterization may play a larger role in shaping treatment strategies. Ongoing research efforts, including cooperative group studies, aim to determine whether these subtypes can guide more personalized treatment approaches in the future. The discussion concluded with a call for continued infrastructure development in community oncology.
Nat'l Media , Historic EventI am BOTH a Northerner & present Washingtonian who was born after the Historic Marches for My Civil Rights to Vote, Education, Public Accommodations,Transportation & EmploymentMajor Media Nationally & Internationally covered in the Marches. Citizens & Celebrities also participated:Joan Baez, James Baldwin, Harry Belafonte, Tony Bennett, Leonard Bernstein, Sammy Davis, Jr., Billy Eckstein, Dick Gregory, Lena Home, Mahalia Jackson, William Marshall, Johnny Mathis, Nina Simone, Susan Sarandon, Pernell Roberts, Peter,Paul & Mary....My Guest is the Reverend Clarence Varner who was in Grade School when he joined the Marches for Civil Rights in the 1960's. Although it cost Him is Part-Time Job while a Teenager, He held on to his Beliefs to Stay in the Fight, even getting Arrested Several times & Tear Gassed, Cattle Prod Shocked, Attack Dogs & Fire Hosed because he stood with others to Petition the the Governor for the Right for Blacks to Vote.Rev. Clarence Varner served The United States in the Marine Corps for 8 years & served in during Vietnam during the War , he was wounded. Today he serves his God, Country & Community in the continued fight for Civil Rights*In 1965, Blacks could not: *go to eat, Blacks were served at the Side or Back Door.*Social Movie Theatres, & Clubs too*Schools in the South & other State were Segregated*Housing was Segregated in Much of America. Redlining was the norm.* Thriving Middle Class Black Business's in Black Communities were forced out of Business due to the Federal Highway's that were built OVER that land.* Separate water Fountains & Bathrooms*Separate Transportation on Buses & Trains, etc.* Upper Corporate Jobs were not opened to most Blacks These Marches were ignited by the Death of SCLC local Jimmie Lee JacksonWhat did Jimmie Lee Jackson accomplish?Jimmie Lee Jackson, was a Vietnam veteran, Baptist deacon, activist and martyr of the Civil Rights Movement. Jackson, active in the fight for equal rights, had tried multiple times to register to vote in Alabama and was denied each time.When Jimmie Lee Jackson saw his frail 80-year-old grandfather rudely turned away from the registrar's office in 1962 after attempting to register to vote in Marion, Ala. He knew he had to join the civil rights movement.On Feb. 18, 1965, he was among more than 200 people participating in a night march in Marion. Before they had walked a block, they were confronted by state troopers and the police chief, who ordered them to disperse.Jackson and his mother huddled for safety in a café. When Jackson's grandfather entered the café bloodied and beaten, the young man tried to take him to a hospital. But they were quickly shoved back by a crowd of club-swinging troopers and terrified marchers. Another trooper pulled his pistol and shot Jackson in the stomach. It was two hours before Jackson arrived at the hospital in Selma. He died eight days later.At one of two services for Jackson, Dr. Martin Luther King Jr. told a crowd of 2,000: “Jimmie Lee Jackson's death says to us that we must work passionately and unrelentingly to make the American dream a reality. His death must prove that unmerited suffering does not go unredeemed.”© 2026 Building Abundant Success!!2026 All Rights ReservedJoin Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASAmazon Music ~ https://tinyurl.com/AmzBASAudacy: https://tinyurl.com/BASAud
Time Magazine, CNN, Media Images & Reporting Reflect the Colors of Change.This Week I Take Time to Reflect & Just Breathe. Also Reflect of Things Happening in Our World. In Remembrance of Jimmie Lee Jackson & The Late Honorable John Lewis (D,GA).In 2026, We are STILL Fighting the Good Fight for Voter's Rights for ALL.I have been Blessed to Meet, Learn, Train & Work along side of Several Civil Rights Icons. On of them was the Late The Honorable John Lewis (D,GA) who Fought & Marched in 2020 to the Very End!!I have attended events Remembering the History, People & Sacrifice.The Fight for Justice Continues Today in 2026 as People Help Bring About Change.My Guest this Week was asked to join the Selma March in Alabama in 1965 by Dr. Martin Luther King. His name: Joseph Cooney Esq., then a newly ordained Priest. He also worked with SCLC in the Voters Registration Summers of 1966-67.In 1965, State Troopers Clashed with Citizens marching to Montgomery, Alabama to petition the state for African-American's Right to Vote. Many lives would change in this fight. Some lives both Black & White lost. The March from Selma to Montgomery was inspired by the death of Jimmie Lee Jackson was a civil rights activist in Marion, Alabama, and a deacon in the Baptist church. On February 18, 1965, while participating in a peaceful voting rights march in his city, he was beaten by troopers and shot by Alabama State Trooper John Bonard Fowler Jackson was unarmed and died eight days later in the hospital.His death was part of the inspiration for the Selma to Montgomery marches in March 1965, a major events in the American Civil Rights Movement that helped gain Congressional passage of the Voting Rights Act of 1965. This opened the door to millions of African Americans being able to vote again in Alabama and across the South, regaining participation as citizens in the political system for the first time since the turn of the 20th century, when they were disenfranchised by state constitutions and discriminatory practices.© 2026 Building Abundant Success!!© 2026 All Rights Reserved Join Me on ~ iHeart Media @ https://tinyurl.com/iHeartBAS Spot Me on Spotify: https://tinyurl.com/yxuy23baAmazon ~ https://tinyurl.com/AmzBASAudacy: https://tinyurl.com/BASAud
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00) Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13) Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21) Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46) Clinician Survey Results (32:16) Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39) Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20) Promising Investigational Strategies — Dr Chiang (49:14) CME information and select publications
In today's episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Haven, Connecticut.In our exclusive interview, Chiang reflected on how the field has shifted since the introduction of chemoimmunotherapy in 2018, highlighting improvements in median overall survival and the emergence of long-term responders in extensive-stage disease. Chiang also explored the growing understanding of disease heterogeneity, and the evolution of biomarker-informed strategies like under evaluation in the phase 2 S2409 PRISM trial (NCT06769126).Additionally, Chiang examined the clinical effect of DLL3-targeted therapies, including the recently approved bispecific antibody tarlatamab-dlle (Imdelltra), and how surface-targeting strategies are expanding options beyond traditional chemotherapy. Beyond efficacy, Chiang underscored the importance of individualized decision-making by assessing patient fitness beyond ECOG performance status, navigating treatment urgency in rapidly progressive disease, and balancing durability with toxicity when counseling patients on therapy.
Are you up to date on the management of extensive-stage small cell lung cancer (ES-SCLC)? Credit available for this activity expires: 2/20/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/quick-talk-es-sclc-what-community-clinicians-need-know-now-2026a100055m?ecd=bdc_podcast_libsyn_mscpedu
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XYC865. CME/MOC/AAPA credit will be available until January 29, 2027.The ADC Wave in SCLC: Emerging Evidence and Practical Considerations for New Options on the Horizon In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Daiichi Sankyo, Inc., and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
Are you up to date with the latest management for extensive-stage small cell lung cancer? Credit available for this activity expires: 2/11/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/case-case-managing-es-sclc-real-world-through-patient-2026a10003ro?ecd=bdc_podcast_libsyn_mscpedu
CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/ This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinical trial data on B7-H3–directed antibody-drug conjugates in ES-SCLC, including key efficacy and safety outcomes in pretreated populations. Learners will gain practical guidance on identifying appropriate candidates for these therapies based on trial eligibility and real-world considerations. Emphasis is placed on interprofessional management of treatment-related adverse events to elevate patient safety and continuity of care.=
In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.
This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease. Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.
Curtis Yarvin claims key civil rights institutions were shaped by former Communist Party operatives, pointing to Stanley Levison's role advising MLK and the SCLC. He argues American political narratives often hide uncomfortable realities, comparing media control, propaganda, and mythmaking across the 20th century.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
As Barry Manilow's recent lung cancer diagnosis reminded us, a persistent cough, chest pain, shortness of breath may be more than just annoying symptoms. In this episode, we explain the signs you shouldn't ignore, what testing and treatment may look like, and how hope is still part of the story. https://bit.ly/4szFIiaIn this Episode:02:21 - Tips for Longevity from People in their 90's - Naomi Rose & Physical Fitness04:48 - Avocado Salsa: Marriage of Guacamole and Pico de Gallo05:47 - Barry Manilow's Lung Cancer Diagnosis07:05 - Review of Lung Anatomy, Lung Cancer Overview, Differences between NSCLC and SCLC 09:32 - What Increases Our Risk of Lung Cancer?10:35 - Lung Cancer Signs and Symptoms to Watch For12:49 - Treatment of Lung Cancer - Reasons for Hope15:46 - Cancer Survivorship: How to Lower Your Risk of Cancer Returning and Signs not to Ignore18:57 - Discussion with Charlie: Historical Smoking, Persistent Cough24:04 - 27 y.o. Alexa Bekkerus Self-Written Obituary - How She Found Peace Dying with Metastatic Breast Cancer29:21 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
Voters Right Act, Chicago Tribune, Slate, NY TimesAugust 6th, 1965 the Voting Rights Act was Signed by President Lyndon B. Johnson., C.T. Vivian, a prominent figure in the Civil Rights Movement, was violently attacked by Sheriff Jim Clark while attempting to escort a group of African Americans to register to vote. Steve Fiffer is a New York Times Bestselling Author. His Book is "It's in The Action": Memories of a Nonviolent Warrior, Rev C.T. Vivian's Memoir.Reverend Vivian was a Major Force in the Fight for Civil Rights & Voters Rights in the Twentieth Century till he Passed July 17th, 2020.Regardless of Social Status, Party Affiliation or Belief, Race: Libertarian, Democrat, Progressive or Republican or Other, All Americans Should Have the Right to Vote!Senator Barack Obama, speaking at Selma's Brown Chapel on the March 2007, anniversary of the 1965 Selma to Montgomery marches, recognized Vivian in his opening remarks in the words of Martin L. King Jr. as "the greatest preacher to ever live."Studying for the ministry at American Baptist Theological Seminary (now called American Baptist College) in Nashville, Tennessee, in 1959, Vivian met James Lawson, who was teaching Mohandas Gandhi's nonviolent direct action strategy to the Nashville Student Movement. Soon Lawson's students, including Diane Nash, Bernard Lafayette, James Bevel, John Lewis and others from American Baptist, Fisk University and Tennessee State University, organized a systematic nonviolent sit-in campaign at local lunch counters.Vivian helped found the Nashville Christian Leadership Conference, and helped organize the first sit-ins in Nashville in 1960 and the first civil rights march in 1961. In 1961, Vivian participated in Freedom Rides. He worked alongside Martin Luther King Jr. as the national director of affiliates for the SCLC. During the summer following the Selma Voting Rights Movement, Vivian is perhaps best known for, Vivian challenged Sheriff Jim Clark on the steps of the courthouse in Selma, Alabama, in 1965 during a drive to promote Black people to register to vote."You can turn your back on me, but you cannot turn your back upon the idea of justice," Vivian said to Clark as reporters recorded the interaction. "You can turn your back now and you can keep the club in your hand, but you cannot beat down justice. And we will register to vote, because as citizens of these United States we have the right to do it."Vivian conceived and directed an educational program, Vision, and put 702 Alabama students in college with scholarships (this program later became Upward Bound). His 1970 Black Power and the American Myth was the first book on the Civil Rights Movement by a member of Martin Luther King's staff.On August 8, 2013, President Barack Obama named Vivian as a recipient of the Presidential Medal of Freedom.Steve's own Memoir is "Three Quarters, Two Dimes, and a Nickel". His work has appeared in Chicago Tribune. & Slate. He's also a Guggenheim Fellow© 2026 All Rights Reserved© 2026 Building Abundant Success!!Join Me on ~ iHeart Media @ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23baAmazon Music ~ https://tinyurl.com/AmzBASAudacy: https://tinyurl.com/BASAud
In today's episode I sit down with Frank, Kathie and Jonny Muse and talk with them about how they came to be the business they are today. Frank and Kathie have worked together for many years, and they wouldn't want it any other way. Building and growing a business for them has always been about family, treating their employees and customers right, and never being a single service outfit.We also talk about their involvement in the Sierra Cascade Logging Conference and how they've grown strong connections between industry and the community through their work with the SCLC. The annual Forest Products and Construction Equipment Expo will be held at the Shasta District Fair & Event Center in Anderson, California from Thursday February 5th to Saturday February 7th, 2026. The area will be filled with vendors from all sides of the industry, a log loading competition and an excavator rodeo. You won't want to miss this event.I would like to thank Frank, Kathie and Jonny for taking time out of their busy day to sit down and chat with me.
In today's episode, we had the pleasure of speaking with Jacob Sands, MD, and Shailee Shah, MD, about considerations for diagnosing and managing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC). Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the Oncology Medical Director of the International Patient Center at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In our exclusive interview, Drs Sands and Shah discussed LEMS symptom identification, the importance of paraneoplastic panels for assessing neurologic dysfunction in patients with SCLC, the need for specific autoantibody testing, and what guidelines currently note as best practices for the diagnosis of this disease.
The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
ABOUT THIS EPISODE Who is a pharmacist, and how are they involved in the care of neuroendocrine cancer patients? In this episode, Dr. Amanda Cass, a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt Medical Center, explains the unique role pharmacists play—why they're sometimes called “doctor,” how they support patients starting treatments such as cabozantinib and CAPTEM, and practical tips for staying organized, managing side effects, and navigating medication costs. TOP TEN QUESTIONS Getting to Know the Pharmacist1. What exactly does a pharmacist do, and what training do they go through?2. Why are pharmacists sometimes called “doctor,” and how is that different from a physician? 3. What role does a pharmacist play on the cancer care team? 4. How are pharmacists involved in caring for neuroendocrine cancer patients, both directly and behind the scenes?How Pharmacists Support Treatment5. How can a pharmacist help when someone is starting a new treatment for neuroendocrine cancer? Walk us through an example with Cabozantinib: how do you guide patients in understanding it, taking it, and managing side effects?6. Walk us through another example with CAPTEM (capecitabine and temozolomide): how do you guide patients in understanding it, taking it, and managing side effects?Practical Tips for Patients7. What are some simple ways to stay organized, like keeping a medication list or symptom journal? 8. What practical tips do you share with patients about tracking and managing side effects at home?Access and Communication9. Who can patients talk to about medication costs or financial assistance?10. How does someone find a pharmacist to talk to, and is it important to find one with neuroendocrine cancer experience?ABOUT AMANDA CASSDr. Cass is a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center.Dr. Cass's previous research interests included opioid use in non-metastatic cancer patients after curative treatment and albumin effects on oxaliplatin related toxicities. Her current areas of interest are molecular mutations and use of targeted therapies in NSCLC, immunotherapy in SCLC, and global oncology care.Dr. Cass is the preceptor for the Outpatient Thoracic Oncology Rotation.For more information, visit NCF.net/podcast/50For more information, visit NCF.net.
George E. Shinhoster came of age in the civil turbulence of the 1960s. A native of Savannah, Ga., he was one of the first African Americans to desegregate a high school and college there. He worked with the Chatham County Crusade for Voters to register black citizens to become voters. In the heat of the civil rights struggle, Mr. Shinhoster worked with the Rev. Dr. Martin Luther King Jr. and the Southern Christian Leadership Conference as a field organizer in Georgia, Florida, Alabama, Mississippi and South Carolina. After joining the SCLC, George endured arrest 19 times in pursuit of voting rights and equal access to public accommodations for black people throughout the South. He marched with Dr. King, experiencing firsthand his leadership, commitment, and drive in the midst of the struggle. George worked with the YMCA for 42 years as an executive in Georgia, South Carolina, Washington state, and North Carolina, before retiring as president and CEO of the Newark YMCA in New Jersey in 2011. He was also a national trainer and facilitator for the YMCA. Today, he is president of The George Shinhoster Experience, an enterprise that highlights Mr. Shinhoster's exploits through speaking, storytelling, and facilitation. He is also a principal of the Earl T. Shinhoster Youth Leadership Institute, preparing middle and high school students to become leaders in their schools and communities. Throughout his travels across the country, in Africa and in Canada, Mr. Shinhoster energizes audiences with lessons he learned from the early civil rights movement. He is a keeper of the dream of Dr. King and believes that while much as been accomplished, much more remains to be done.
George E. Shinhoster came of age in the civil turbulence of the 1960s. A native of Savannah, Ga., he was one of the first African Americans to desegregate a high school and college there. He worked with the Chatham County Crusade for Voters to register black citizens to become voters. In the heat of the civil rights struggle, Mr. Shinhoster worked with the Rev. Dr. Martin Luther King Jr. and the Southern Christian Leadership Conference as a field organizer in Georgia, Florida, Alabama, Mississippi and South Carolina. After joining the SCLC, George endured arrest 19 times in pursuit of voting rights and equal access to public accommodations for black people throughout the South. He marched with Dr. King, experiencing firsthand his leadership, commitment, and drive in the midst of the struggle. George worked with the YMCA for 42 years as an executive in Georgia, South Carolina, Washington state, and North Carolina, before retiring as president and CEO of the Newark YMCA in New Jersey in 2011. He was also a national trainer and facilitator for the YMCA. Today, he is president of The George Shinhoster Experience, an enterprise that highlights Mr. Shinhoster's exploits through speaking, storytelling, and facilitation. He is also a principal of the Earl T. Shinhoster Youth Leadership Institute, preparing middle and high school students to become leaders in their schools and communities. Throughout his travels across the country, in Africa and in Canada, Mr. Shinhoster energizes audiences with lessons he learned from the early civil rights movement. He is a keeper of the dream of Dr. King and believes that while much as been accomplished, much more remains to be done.
© 2020-2026 Ivy Podcast Discovery LLC
